Letrozole Torrent Pharma (Uk) (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogen. By inhibiting this conversion, circulating estrogen concentrations fall, depriving estrogen‑dependent breast cancer cells of the hormonal stimulus they need to proliferate.

The specific dose and schedule of Letrozole are determined by the prescribing clinician based on the patient’s condition, treatment stage, and overall health. Patients should follow the exact regimen provided by their healthcare professional.

Letrozole is contraindicated in pregnancy because it can affect fetal development. It is also not recommended while breastfeeding, as it may pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To request Letrozole Torrent Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Letrozole is a third‑generation aromatase inhibitor, offering more potent estrogen suppression than earlier agents such as anastrozole. Compared with selective estrogen receptor modulators like tamoxifen, Letrozole does not act on estrogen receptors directly, which can result in different side‑effect profiles and efficacy in postmenopausal patients.

Letrozole tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct light. Keep the product out of reach of children and do not use if the packaging is damaged.

Letrozole is taken orally, usually as a single tablet once daily, with or without food. Patients should swallow the tablet whole with water and avoid crushing or chewing it, unless otherwise instructed by a healthcare professional.

Serious risks include severe liver injury, bone fractures due to decreased bone mineral density, and rare thromboembolic events such as pulmonary embolism. Patients should report any signs of liver dysfunction, unexplained bone pain, or sudden shortness of breath to their physician promptly.

Letrozole is not recommended for premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to the drug. It should also be avoided in patients with severe liver impairment or uncontrolled cardiovascular disease unless a specialist determines the benefits outweigh the risks.